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ABSTRACT
Rat pulmonary artery endothelial cells incubated with
human serum that has been complement-activated by
addition of cobra venom factor reveal a pronounced
conversion of xanthine dehydrogenase to xanthine oxi-
dase. This process requires the availability of the fifth
component of complement (C5) but not the presence
of other components (C2 and C6-C9). The phenome-
non can be reproduced by addition to endothelial cells
of purified human recombinant C5a but not C5a
desArg or C3a. The enzyme conversion process is rela-
tively rapid (occurring within 5-10 mm), requires the
presence of intact endothelial cells, and does not re-
quire protein synthesis. Similar effects on endothelial
cells have been obtained with human recombinant
tumor necrosis factor a and the chemotactic peptide N-
formyl-Met-Leu-Phe. In contrast, bradykinin, recom-
binant human interleukin 113, and phorbol ester lack
this biological activity. These findings suggest novel
effects of inflammatory mediators on endothelial cells.
-FRIEDL, H. P.; ‘IILL, G. 0.; RYAN, U. S.; WARD,
P. A. Mediator-induced activation of xanthine oxidase
in endothelial cells. FASEBJ 3: 2512-2518; 1989.
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tumor necrosis factor
XANTH!NE OXIDASE (XO)2 (EC 1.1.3.22) appears to play
an important role in events related to ischemia-reper-
fusion injury in a variety of organs (reviewed in ref 1).
It has been demonstrated that this enzyme is derived by
cleavage or by reversible oxidation of xanthine de-
hydrogenase (XD) (ECI.l.l.204) (2, 3) and that the
products of XO (superoxide anion and its conversion
products, H2O2 and the hydroxyl radical) are either
directly toxic to tissues or participate in generation of
chemotactic lipids, which cause recruitment of neutro-
phils (1, 4, 5). In turn, oxygen products from activated
neutrophils injure tissues (6). XO has been found in
certain species of endothelial cells (7-9), and recently it
has been shown that the interaction of activated neu-
trophils with endothelial cells results in conversion of
XD to XO within endothelial cells (10). This process
appears to have biological implications, as the killing of
endothelial cells by activated neutrophils can be attenu-
ated if endothelial cells are pretreated with inhibitors of
XO (10). The ultimate killing of endothelial cells by ac-
tivated neutrophils is related to H2O2 production by
neutrophils (11).
In this study we show for the first time that peptide
chemotactic mediators can interact directly with endo-
thelial cells to bring about activation of XO (i.e., the
conversion of XD to XO). These data suggest that these
inflammatory mediators have bidirectional effects, both
on phagocytic cells as well as on potential targets such
as endothelial cells, to bring about inimical conse-
quences of the inflammatory response.
MATERIALS AND METHODS
Materials
Unless otherwise stated, enzymes and reagents were
purchased from Sigma Chemical Corp. (St. Louis,
Mo.) and were of the highest purity available. Com-
plement-deficient sera were obtained from Cytotech
(San Diego, Calif.). Recombinant human necrosis fac-
tor a (rTNF-a) was purchased from Amgen Corp.
(Thousand Oaks, Calif.) and recombinant interleukin
1/3 (IL 1/3) from Cistron (Pine Brook, N.J.). Recom-
binant human C5a was donated by H. Showell (Pfizer
Corp., New London, Conn.). C3a was of synthetic ori-
gin containing residues 55-77 and was a gift from
Dr. M. M. Glovsky, University of Southern California
School of Medicine.
‘To whom correspondence should be addressed, at: Department
of Pathology, The University of Michigan Medical School, 1301
Catherine St., Ann Arbor, MI 48109-0602, USA.
2Abbreviations: BSA, bovine serum albumin; CVF, cobra venom
factor; DTT, dithiothreitol; EACA, e-amino-n-caproic acid; fMLP,
formyl-methionyl-leucyl-phenylalanine; HBSS, Hanks’ balanced
salt solution; NHS, normal human serum; PMSF, phenylmethyl
sulfonyl fluoride; RPAEC, rat pulmonary artery endothelial cells;
XD, xanthine dehydrogenase; X0, xanthine oxidase; IL 1, interleu-
kin 1; PBS, phosphate buffered solution; rTNF-a, recombinant
human tumor necrosis factor a; PBS, phosphate-buffered saline;
rIL 1, recombinant human interleukin l.
Endothelial cells DNA assay
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Rat pulmonary artery endothelial cells (RPAEC) were
obtained as described in ref 12. The isolated cells grew
with a cobblestone morphology as evidenced at both
the light and electron microscopic levels and were
identified as endothelia! cells by the presence of angio-
tensin-converting enzyme activity and reactivity with
antibodies to factor VIII (13, 14). The cells were main-
tained in monolayer culture at 37#{176}Cand 5% CO2
using Ryan red medium. For enzyme assays, cells were
plated onto 35-mm wells of six-well plates and allowed
to grow to confluence overnight. On the day of the as-
say, media were removed and the cells washed three
times with Hanks’ balanced salt solution (HBSS) con-
taining 0.02% bovine serum albumin (BSA). A final
volume of 2 ml of fluid was used in each well containing
monolayers of endothelial cells. Where stated, allo-
purinol was added to RPAEC monolayers. The plates
contained approximately 1.0 x 106 RPAEC per well
and were maintained under the appropriate experi-
mental conditions at 37#{176}Cin a CO2 incubator for 60
mm. Media were then removed and the wells gently
washed twice with phosphate-buffered saline (PBS) and
the fluid removed. Finally, 100 jtl of ice-cold extraction
buffer containing 0.05 M sodium pyrophosphate, 1 mM
EDTA, 0.2% (v/v) Triton X-100 (Aldrich Chemical Co.,
Milwaukee, Wis.), 10 mM dithiothreitol (DTT), and
1 mM phenylmethyl sulfonyl fluoride (PMSF) were
added into each well to achieve cell lysis and extraction
as described in ref 15. Aliquots were taken from each
sample and assayed for uric acid formation in the pres-
ence and absence of NAD as outlined below.
Cobra venom factor
Cobra venom factor (CVF) was isolated from crude
lyophilized cobra (Naja naja) venom by ion exchange
chromatography and gel filtration (16). It was used to
activate complement in human sera during incubation
with endothelial cells.
Xanthine dehydrogenase/xanthine oxidase activity
XD and XO activities were assayed spectrophotometri-
cally (Gilford Response II, Ciba Corning Diagnostics
Corp., Oberlin, Ohio, Gilford software V6.04 with ad-
vanced enzyme kinetics) by continuous measurement
of uric acid formation at 293 nm in the presence or ab-
sence of NAD at 37#{176}C,as described (15, 17). The re-
action mixture contained 100 tl xanthine (50 tM), 100
tl NAD (500 tM) or buffer in the absence of NAD,
600 tl potassium phosphate (2.4 mM) and sodium
chloride (150 mM) at pH 7.35, and 100 tl cell lysate.
The reaction mixture also contained 100 jil of the un-
case inhibitor, 2 ,4-dihydroxyl-6-carboxy-1,3 ,5 triazine
(Aldrich Chemical Co.), present in a final concentra-
tion of 3 jiM (18). XO and XD activities were expressed
as [nmol uric acid formed. 1.0 x 106 RPAEC1 . min].
Confirmation of the number of RPAEC in each sample
was achieved by the fluorometric analysis of cell lysates
at 458 nm by using bisbenzimide (Hoechst 33258) as
an indicator substance (19). If necessary, enzyme activi-
ties were adjusted for a cell number equivalent to
1.0 x 106 RPAEC per sample. The cell number rarely
varied from well to well by more than 5%.
Preparation of C5a desArg
C5a desArg was prepared by incubating recombinant
human C5a (0.6 jiM) for 10 mm at 37#{176}C,pH 7.35,
with insoluble carboxypeptidase N (EC 3.4.17.3) (0.5
U/ml) attached to agarose beads. After the incubation,
carboxypeptidase N was removed by centrifugation.
The supernatant (containing C5a desArg) was stored
on ice until used in further experiments; the pellet was
discarded.
Interleukin 1
Biological activity of interleukin 1 (IL 1) was deter-
mined in the thymocyte proliferation assay. One unit
was defined as the amount of recombinant human IL I
that caused half-maxima! incorporation of [3Hjthymi-
dine by murine (C3H) thymocytes in the presence of
concanavalin A (0.5 ig/ml) (20).
Statistical analysis
Data from various groups were expressed as mean ±
SEM. A paired Student’s 1-test was used to compare the
response between two groups. To determine the sig-
nificance of differences between controls and multiple
experimental groups, two-way analysis of variance in
combination with the Dunnett’s multiple comparisons
test was used. Statistical significance was defined as
P < 0.05. Specifics regarding the number of experi-
ments and other relevant information appear elsewhere
in the text or in Tables 1-3.
RESULTS
Complement activation and conversion of
XD to XO in endothelial cells
In lysates of RPAEC incubated in HBSS in the
presence or absence of five units of CVF, enzyme activi-
ties for both XD and XO could be readily detected at
a ratio of approximately 1:1 (Table 1). Addition of CVF
(with complement activation) in the absence of serum
did not alter this ratio. The pattern was essentially un-
changed by the addition of normal human serum
(NHS) to RPAEC, but in the copresence of CVF there
was a dramatic shift in the XO to XD ratio, from 1.21
to 6.13. It should be noted that the total enzyme activity
(XD + XO) remained unchanged. Prior heat inactiva-
tion of complement prevented the ability of CVF, when
TABLE 1. Complement-deficient sera in the presence and absence of CVF and conversionof xanthinedehydrogenasetoxanthineoxidase#{176}
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No. of
Without comple ment activation With complem ent activationt
Pretreatment of endothelial cells experiments XO’ XD’ XO’ XD’
HBSS 8 3.28 ± 0.34 2.94 ± 0.26 3.39 ± 0.42 2.86 ± 0.24
Normal human serum (NHS)
NHS, heat-inactivated1
10
8
3.31
3.38
± 0.32”
± 0.30”
2.73
2.76
± 0.28”
± 0.30”
5.28
3.46
± 0.84’
± 0.39”
0.86
2.59
± 0.19’
± 0.29”
NHS + allopurinol 8 0.24 ± 0.036’ 0.26 ± 0.040’ 0.36 ± 0.039’ 0.29 ± 0.039’
C2-deficient serum 8 3.52 ± 0.77” 2.61 ± 0.34” 5.36 ± 0.92’ 0.92 ± 0.14’
C5-deficient serum 10 3.29 ± 0.54” 2.69 ± 0.26” 3.34 ± 0.68” 2.66 ± 0.34”
C6-deficient serum 8 3.24 ± 0.52” 2.84 ± 0.30” 4.98 ± 0.80’ 1.12 ± 0.19’
C7-deficient serum 8 3.36 ± 64d 2.86 ± 0.34” 5.00 ± 0.86’ 1.04 ± 0.21’
C8-deficient serum 8 3.30 ± 0.58” 2.68 ± 0.36” 5.12 ± 0.92’ 0.94 ± 0.20’
C9-deficient serum 8 3.38 ± 0.54” 2.62 ± 0.34” 5.18 ± 0.90’ 0.96 ± 0.22’
AII experiments were conducted in the presence of EACA (10 mM) and a 10% content (v/v) of serum in the incubation mixture. bComplement
activation was achieved by addition of 5 U CVF/ml prior to incubation of serum with endothelial cells. ‘ x + SEM in: Inmol. 1.0 x 106
RPAEC’ minl. “P > 0.05 compared with corresponding control (HBSS). ‘P < 0.05 compared with corresponding control (HBSS). 1Heat
inactivation was achieved by heating the serum for 30 mm at 56#{176}prior to incubation with endothelial cells.
added to serum, to convert XD to XO. Not Surprising-
ly, in the presence of allopuninol, both XD and XO
were inhibited and the subsequent addition of CVF to
the serum did not alter this pattern.
Human sera that were selectively deficient (>95%)
in complement components (C2, C5, C6-C9) were
used to define the selective component requirements
for the enzyme conversion process. The results are also
shown in Table 1. Because CVF activates complement
via the alternative pathway, it was not surprising that
C2 was not required for the conversion of XD to XO.
However, CS-deficient serum failed completely to sup-
port the ability of CVF-treated serum to convert XD to
XO, whereas serum deficient in the more distal comple-
ment components (C6-C9) permitted the full conver-
sion process to occur. These results strongly suggest
that a C5-dependent product of complement activation
(e.g., C5a) but not a more distal activation product
(C5b-C9) is responsible for the conversion of XD to
XO in endothelial cells.
C5a-induced conversion in endothelia! cells of
XD to XO; inactivity of C5a desArg
Since it seemed likely that the CS activation product,
C5a, was responsible for the results described in Table I,
human recombinant C5a was evaluated for its ability to
convert XD to XO in RPAEC. As shown in Figure 1A,
very low (nM) amounts of C5a were able to bring
about conversion of XD to XO in endothelial cells. In-
terestingly, when much higher concentrations of C5a
were used, conversion of XD to XO still occurred, but
this conversion process was attenuated under such con-
ditions. The same phenomenon will be apparent in the
case of rTNF-a and formyl-methionyl-leucyl-phenyl-
alanine (fMLP) (see below). Confirmation that CSa in-
duces an increase in superoxide-generating activity was
obtained with endothelial cells exposed to HBSS or to
I nM C5a. The superoxide-inhibitable reduction of
ferricytochrome c was assessed as detailed elsewhere
(15). Under these conditions superoxide-generating
activities in lysates of endothelial cells exposed to
HBSS or C5a were 2.82 and 5.14 nmol O2 I x 106
cellst . min’, respectively, which is very similar to the
data in Table 1 (NHS + CVF).
The declining chemotactic response of cells expands
to progressively increasing concentrations of C5a, and
fMLP is well-documented in the case of neutrophils
(21), similar to the phenomenon involving endothelial
cells (Fig. IA). Furthermore, conversion of XD to XO
failed to occur when C5a desArg was employed (Fig.
IB), implying a high degree of structural specificity for
the C5a molecule, similar to requirements of intact
C5a for spasmogenic effects on smooth muscle and
chemotactic responsiveness of neutrophils (reviewed in
ref 22). Finally, incubation of lysates of RPAEC with 10
nM CSa failed to result in conversion of XD to XO,
suggesting that intact cells are required for the enzyme
conversion process (data not shown).
It has been shown that signal transduction events
(expression of intercellular adhesion molecules) in en-
dothelial cells induced by tumor necrosis factor (23)
represent slow responses that require hours of time for
full expression and active protein synthesis, and so we
evaluated the time course and the requirement for pro-
tein synthesis in conversion of XD to XO in RPAEC
treated with CSa. The time course for this conversion
was relatively rapid, measurable at s mm and complete
by 10 mm (Fig. 2A). Furthermore, there was no evi-
dence for the requirement of protein synthesis for this
conversion process, since in RPAEC pretreated with
cycloheximide C5a was able to cause virtually complete
conversion of XD to XO (Table 2).
Comparison of ability of inflammatory peptide
mediators to activate endothelia! cells
As both bradykinin and tumor necrosis factor have
been found to stimulate endothelial cells (23-26), we
compared the ability of a variety of chemotactic peptide
mediators and phorbol ester to react with RPAEC and
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Figure 1. Dose-responses for C5a (A) and C5a desArg (B) induced
conversion of XD to X0 in RPAEC. Time of incubation was 60
mm at 37#{176}C.
induce conversion of XD to XO. Dose-responses were
carried out, and the concentration (ED50) of peptide re-
quired to bring about 50% conversion of XD to XO
was calculated. The results are shown in Table 3. Syn-
thetic C3a, which contains the COOH-termina! amino
acid residues 57 to 77 and exhibits spasmogenic activity
similar to the intact C3a molecule (27), was unable to
cause conversion of XD to XO in RPAEC. The ED50
for C5a was 4 nM, whereas neither C5a desArg nor
bradykinin exhibited biological activity in this system
(ED50 > 1000 nM). rTNF-a was active with an ED50 of
12 nM whereas recombinant human interleukin 1/3
(rIL 1/3) and phorbol ester (PMA) were inactive. The
chemotactic peptide N-formyl-Met-Leu-Phe was also
active (ED50 of 46 nM) in this biological system. Thus,
three peptide chemotactic mediators (C5a, rTNF-a,
and fMLP) that cause signal transduction events in
phagocytic cells (e.g., neutrophils, macrophages) also
bring about activation events in endothelial cells.
The ability of rTNF-a to effect conversion of XD to
XO in RPAEC was further evaluated with respect to
the time course and the dose-response profile. rTNF-a-
induced conversion of XD to XO was well advanced at
10 mm and complete within 15 mm (Fig. 2B), similar
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Figure 2. Time course for conversion of XD to X0 in RPAEC
treated with 8 nM C5a (A) or with 10 nM TNF-a (B).
TABLE 2. Effect of cycloheximide on C5a-induced conversion of XD to XO in endothelial cells
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No. of
Treatment of endothelial cells’ experiments
Enzyme activityt
XO XD P value’
HBSS 10 3.36
HBSS (cycloheximide) 5 3.27
HBSS + C5a 10 5.91
HBSS (cycloheximide) + C5a 5 5.64
± 0.65
± 0.74
± 0.82
± 0.86
3.22 ± 0.26
3.14 ± 0.32
0.64 ± 0.18
0.56 ± 0.16
-
N.S.”
P < 0.01
P < 0.01
‘When cycloheximide was used, endothelial cells were preincubated with 5 x
added. bMean ± SEM, nmol uric acid formation/I x 106 per mm cells(seeMa
10 M drug for I h at 37#{176}Cand washed;
terials and Methods). ‘P values refer t
then C5a or HESS was
o HBSS controls.
to the findings with C5a (Fig. 2A). Dose responses for
conversion of XD to XO by rTNF-a and fMLP are
shown in Figure 3A and Fig. 3B. In the case of rTNF-
a, maxima! conversion was found at a concentration of
50 nM whereas maximal conversion with fMLP was
found at a concentration of 100 nM. When compared
side by side, the maximal amount of conversion achiev-
able with C5a was significantly greater than that at-
tained with fMLP (Fig. 3B). Although C5a was able to
induce a maximum of 85% conversion of XD to XO,
the greatest amount of conversion induced by TNFa
and fMLP was 64.3 and 53.4%, respectively. Reasons
for these differences are presently unknown.
DISCUSSION
The ability of endothelia! cells to respond to bradykinin
and TNF has been well documented (23-26). With
TNF, the response is relatively slow, occurring over a
period of several hours and requiring protein synthesis.
In the case of TNF this is associated with the synthesis
and expression of adhesive factors, which facilitate at-
tachment of neutrophils (26). Bradykinin induces rapid
intracellular calcium transients but the generation of
inositol phosphate requires several hours (28). The cur-
rent studies reflect a mechanism in which peptide
mediators can cause a rapid signal transduction-type of
response, which results in conversion of XD to XO in
endothelial cells. The functional significance of this cell
requirement may be linked to recent studies indicating
that the killing of rat pulmonary artery endothelial cells
by activated neutrophils is associated with conversion
TABLE 3. Abilityofpeptidechemotacticmediatorsto causeconversion
of XD to XO in endothelial cells
Mediator tested #{149}ED’
C3a , > 5000 nM
C5a 4nM
C5a desArg
Bradykinin
rTNF-a5
>
>
1000 nM
10000 nM
12 nM
rIL-l3’ > 10000 mU
PMA > 10000 nM
IMLP 46 nM
‘Concentration required to achieve half-maximal conversion of XD.
to XO in RPAEC. bRecombinant human tumor necrosis factor
a. ‘Recombinant human interleukin 1$.
in endothelial cells of XD to XO (10). This process ap-
pears to result in the production of O within endo-
thelia! cells, leading to a reduction of iron to its transi-
tion (redox) state, Fe2, which in turn can react with
H2O2 diffusing into the endothelial cell from the neu-
trophil. This seems to result in formation of the hy-
droxyl radical (HO.), which appears to be highly toxic
to the endothelia! cell. H202 generated exogenously to
the endothelial cell may re4dily diffuse into the endo-
thelial cell to cause breakdown of ATP, providing addi-
tional substrate for XO (29).
It is of interest that the three chemotactic peptide
inflammatory mediators, C5a, TNF-a, and fMLP, can
each bring about signal transduction events in neutro-
phils, resulting in the generation of toxic oxygen prod-
ucts, which are harmful to endothelia! cells as well as to
a variety of other cells and tissues. The data in this
paper suggest that the same mediators can also activate
endothelial cells to bring about conversion of XD to
XO and thereby enhance their production of O2 and
other oxygen products, the result of which will be inten-
sification of endothelia! cell injury. C5a and TNF-a,
which are products of complement activation and stim-
ulated monocytes, respectively, can be generated at the
interface of endothelial cells and blood leukocytes,
which indicates how such products can lead to an
amplification of the inflammatory response by en-
gaging both effector (neutrophils) and target (endo-
thelia!) cells. Although the intravascular generation of
C5a would be expected to lead rapidly to its conversion
to C5a desArg, it seems likely that the formation of C5a
at the interface of the endothelial cell surface would
permit sufficient C5a to react with the endothelial cell
before conversion to C5a desArg. Regardless of the ex-
planation, the data in Table 1 indicate that a C5-
dependent product in activated plasma is effective.
The nature of the process resulting in conversion of
XD to XO is unknown except that this process is rapid
and irreversible, as defined by the. inability of XO to
revert to XD in the presence of DTT. We have recently
found that a similar phenomenon in endothelial cells of
conversion of XD to XO resulting from contact with
activated neutrophils is not related to an oxygen
product from the neutrophil, since cells from patients
with chronic granulomatous disease (a condition in
which there is no respiratory burst following neutrophil
activation) can cause conversion of XD to XO in the
endothelia! cell (10). This implies that neutrophils con-
tain a non-oxygen-dependent factor that is functionally
similar to C5a, TNF-a, and fMLP. In the context of
the inflammatory system, it is rather common that a
variety of mediators have similar functional effects,
which indicates a degree of redundancy in the inflam-
matory response.
The relatively rapid response (occurring within min-
utes) of endothelial cells to TNF-a (as well as to C5a
and fMLP), in contrast to the protracted period (hours)
required for TNF-a to cause induction of intercellular
adhesive molecules (23, 30), suggests that the response
of endothelial cells to peptide mediators such as TNF-a
may be a manifestation of signal transduction events
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in RPAEC treated with TNF-a (A) or with fMLP (B).
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linked to receptor occupancy and that two different re-
ceptors may be involved. Our demonstration that endo-
thelial cells can respond to peptide mediators, which
also stimulate phagocytic cells, underscores the com-
plexity of events underlying how the inflammatory re-
sponse brings about tissue injury and emphasizes the
possibility that the generation of these peptide media-
tors in vivo may result in a multiplicity of events cul-
minating in tissue injury.
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